ES2147567T3 - El empleo de oxidos de 1,2,4-benzotriazina para la preparacion de un medicamento para el tratamiento de tumores. - Google Patents

El empleo de oxidos de 1,2,4-benzotriazina para la preparacion de un medicamento para el tratamiento de tumores.

Info

Publication number
ES2147567T3
ES2147567T3 ES94202693T ES94202693T ES2147567T3 ES 2147567 T3 ES2147567 T3 ES 2147567T3 ES 94202693 T ES94202693 T ES 94202693T ES 94202693 T ES94202693 T ES 94202693T ES 2147567 T3 ES2147567 T3 ES 2147567T3
Authority
ES
Spain
Prior art keywords
treatment
class
clothed
tumor
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94202693T
Other languages
English (en)
Inventor
Martin J Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Application granted granted Critical
Publication of ES2147567T3 publication Critical patent/ES2147567T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA METODOS PARA AUMENTAR LA CITOTOXICIDAD DE UN AGENTE QUIMIOTERAPEUTICO PARA UN TUMOR SOLIDO, SUSCEPTIBLE DE TRATAMIENTO CON EL AGENTE QUIMIOTERAPEUTICO, OMPRENDIENDO LA ADMINISTRACION A UN MAMIFERO QUE TIENE TAL CLASE DE TUMOR, DESDE MEDIA HORA HASTA VEINTICUATRO HORAS, CON ANTERIORIDAD A LA ADMINISTRACION DEL AGENTE QUIMIOTERAPEUTICO, O DE UNA HORA A DOS HORAS APROXIMADAMENTE, DESPUES DE LA ADMINISTRACION DEL AGENTE QUIMIOTERAPEUTICO, DE UNA CANTIDAD DE REFORZAMIENTO DE LA CITOTOXICIDAD, DE UN COMPUESTO DE FORMULA I. LA INVENCION TAMBIEN PROPORCIONA EQUIPOS PARA EL TRATAMIENTO DE TALES TUMORES, COMPRENDIENDO UN AGENTE QUIMIOTERAPEUTICO Y UNA CANTIDAD DE REFORZAMIENTO DE LA CITOTOXICIDAD, DE OXIDO 1,22,4 RESENTE INVENCION TAMBIEN PROPORCIONA EL USO DE UN COMPUESTO DE FORMULA I, CAPAZ DE EJERCER UN EFECTO DE REFORZAMIENTO CITOTOXICO SOBRE UN TUMOR CANCERIGENO, PARA LA FABRICACION DE UN MEDICAMENTO, PARA LA ADMINISTRACION TERAPEUTICA A UN MAMIFERO QUE TIENE TAL CLASE DE TUMOR, DESDE MEDIA HORA HASTA UNAS VEINTICUATRO HORAS, CON ANTERIORIDAD AL TRATAMIENTO DE TAL TUMOR CON UN AGENTE QUIMIOTERAPEUTICO.
ES94202693T 1993-09-22 1994-09-19 El empleo de oxidos de 1,2,4-benzotriazina para la preparacion de un medicamento para el tratamiento de tumores. Expired - Lifetime ES2147567T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/125,609 US5484612A (en) 1993-09-22 1993-09-22 Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin

Publications (1)

Publication Number Publication Date
ES2147567T3 true ES2147567T3 (es) 2000-09-16

Family

ID=22420569

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99118533T Expired - Lifetime ES2224517T3 (es) 1993-09-22 1994-09-19 Uso de oxidos de 1,2,4-benzotriazinas para la fabricacion de un medicamento para el tratamiento de tumores.
ES94202693T Expired - Lifetime ES2147567T3 (es) 1993-09-22 1994-09-19 El empleo de oxidos de 1,2,4-benzotriazina para la preparacion de un medicamento para el tratamiento de tumores.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES99118533T Expired - Lifetime ES2224517T3 (es) 1993-09-22 1994-09-19 Uso de oxidos de 1,2,4-benzotriazinas para la fabricacion de un medicamento para el tratamiento de tumores.

Country Status (22)

Country Link
US (4) US5484612A (es)
EP (2) EP0972517B1 (es)
JP (1) JPH07215882A (es)
KR (1) KR100383402B1 (es)
AT (2) ATE193827T1 (es)
AU (1) AU690132B2 (es)
CA (1) CA2132578C (es)
CZ (1) CZ289742B6 (es)
DE (2) DE69433889T2 (es)
DK (2) DK0649658T3 (es)
ES (2) ES2224517T3 (es)
GR (1) GR3034360T3 (es)
HU (1) HUT71119A (es)
IL (1) IL111025A (es)
MY (1) MY112405A (es)
NO (1) NO943524L (es)
NZ (2) NZ299690A (es)
PT (2) PT649658E (es)
RU (1) RU2148406C1 (es)
SG (1) SG52568A1 (es)
SK (1) SK282178B6 (es)
UA (1) UA49787C2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides
US5672702A (en) * 1995-12-04 1997-09-30 Sanofi Process for preparing 3 amino 1, 2, 4-benzotriazine dioxide
EP1014990B1 (en) * 1997-03-07 2006-09-06 Sanofi-Aventis U.S. LLC Antitumor combination of 3-amino-1,2,4-benzotriazine 1,4-dioxide/paclitaxel/platinum
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
DE69841058D1 (de) * 1997-11-14 2009-09-24 Gen Hospital Corp Behandlung von hämatologischen störungen
US6074626A (en) * 1998-03-20 2000-06-13 Molecular Radiation Management, Inc. Radioactive cisplatin in the treatment of cancer
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6819761B1 (en) * 1999-09-16 2004-11-16 Silicon Laboratories, Inc. Programmable constant current “off hook” circuit
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
WO2001046162A2 (de) 1999-12-21 2001-06-28 Ufz Umweltforschungszentrum Leipzig-Halle Gmbh Neue 3-substituierte 1,2,4-benzotriazine, verfahren zu ihrer herstellung und ihre verwendung zur behandlung und prophylaxe von tumorerkrankungen
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
AUPQ641100A0 (en) * 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
RU2166945C1 (ru) * 2000-08-08 2001-05-20 Ефимова Лариса Степановна Радиосенсибилизирующее вещество для лечения онкологических заболеваний
US6586460B1 (en) 2001-04-02 2003-07-01 The Board Of Regents For Oklahoma State University Heteroarotinoids containing urea or thiourea linker
RU2192862C1 (ru) * 2001-05-23 2002-11-20 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Способ лечения больших и мультицентричных ретинобластом
AT412703B (de) 2001-12-04 2005-06-27 Vis Vitalis Lizenz & Handels Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung
NZ521436A (en) * 2002-09-17 2005-07-29 Auckland Uniservices Ltd DNA- targeted benzotriazine 1,4-dioxides and their use in cancer therapy
RU2234916C2 (ru) * 2002-10-29 2004-08-27 Московский областной научно-исследовательский клинический институт Способ лечения онкологических больных
US7138520B2 (en) * 2003-01-13 2006-11-21 Massachusetts Institute Of Technology Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
CA2456569A1 (en) * 2003-03-14 2004-09-14 Auckland Uniservices Limited Benzoazine mono-n-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
RU2243766C1 (ru) * 2003-04-01 2005-01-10 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения рецидивов рака шейки матки
US7816521B2 (en) 2004-03-01 2010-10-19 Auckland Uniservices Limited 1,2,4-benzotriazine-1,4-dioxides
EP1866292B1 (en) * 2005-03-31 2010-12-15 Auckland Uniservices Limited Tricyclic 1,2,4-triazine oxides and compositions therefrom for therapeutic use in cancer treatments
JP2009510165A (ja) * 2005-10-03 2009-03-12 ジェネティックス ファーマシューティカルズ， インク． 低酸素細胞を選択的に枯渇させるための方法
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
US7834178B2 (en) * 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
ES2395401T3 (es) * 2006-03-23 2013-02-12 Tmrc Co., Ltd. kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer
AU2009209515A1 (en) * 2008-01-28 2009-08-06 Milux Holding Sa Blood clot removal device, system, and method
CN102026634B (zh) 2008-04-10 2014-01-22 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
US9316632B2 (en) * 2009-03-17 2016-04-19 Marshall University Research Corporation Methods of screening chemotherapeutic agents and treating cancer
AT511159A1 (de) 2011-02-16 2012-09-15 Selo Medical Gmbh Pharmazeutische zusammensetzungen enthaltend selenit- oder selenathältige verbindungen
EP2800744A4 (en) * 2011-12-07 2015-06-03 Sri Internat Inc BENZOTRIAZINE OXIDE AS A MEDICAMENT AGAINST MYCOBACTERIUM TUBERCULOSIS
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
US10947196B2 (en) 2019-03-27 2021-03-16 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
EP3993878A4 (en) * 2019-07-01 2023-11-08 Curasen Therapeutics, Inc. BETA-ADRENERGIC AGONIST AND RELATED METHODS OF USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001410A (en) * 1972-02-01 1977-01-04 Bayer Aktiengesellschaft 3-amino-1,2,4-benzotriazine-1,4-di-n-oxide compositions and method of using same
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
US4923878A (en) * 1988-11-14 1990-05-08 Merck & Co., Inc. Quinolizine sulfonamides used against certain neoplastic disease states
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides

Also Published As

Publication number Publication date
SK114894A3 (en) 1995-11-08
US6277835B1 (en) 2001-08-21
CA2132578C (en) 1998-10-13
DE69433889T2 (de) 2005-06-30
IL111025A (en) 2006-04-10
KR950007853A (ko) 1995-04-15
RU94034104A (ru) 1996-11-10
IL111025A0 (en) 1994-11-28
EP0649658B1 (en) 2000-06-14
ES2224517T3 (es) 2005-03-01
HUT71119A (en) 1995-11-28
DE69424915D1 (de) 2000-07-20
NZ299690A (en) 1997-11-24
AU690132B2 (en) 1998-04-23
CZ232694A3 (en) 1995-09-13
PT972517E (pt) 2004-11-30
DE69433889D1 (de) 2004-08-12
NO943524D0 (no) 1994-09-22
DK0649658T3 (da) 2000-09-11
EP0649658A1 (en) 1995-04-26
ATE193827T1 (de) 2000-06-15
ATE270553T1 (de) 2004-07-15
UA49787C2 (uk) 2002-10-15
AU7411794A (en) 1995-04-06
US5484612A (en) 1996-01-16
RU2148406C1 (ru) 2000-05-10
GR3034360T3 (en) 2000-12-29
EP0972517B1 (en) 2004-07-07
CA2132578A1 (en) 1995-03-23
SG52568A1 (en) 1998-09-28
JPH07215882A (ja) 1995-08-15
SK282178B6 (sk) 2001-11-06
DK0972517T3 (da) 2004-11-08
PT649658E (pt) 2000-12-29
KR100383402B1 (ko) 2003-09-22
CZ289742B6 (cs) 2002-03-13
US6121263A (en) 2000-09-19
NZ264502A (en) 1997-06-24
NO943524L (no) 1995-03-23
MY112405A (en) 2001-06-30
HU9402726D0 (en) 1994-12-28
DE69424915T2 (de) 2001-01-18
EP0972517A3 (en) 2000-01-26
EP0972517A2 (en) 2000-01-19
US5670502A (en) 1997-09-23

Similar Documents

Publication Publication Date Title
MY112405A (en) Method of tumer treatment.
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
FI974268A0 (fi) Flavanolignaanien käyttö lääkkeiden, joilla on lisääntymistä torjuvaa vaikutusta kohdussa, munasarjoissa ja rintarauhasessa, valmistamiseksi
BR9106977A (pt) Metodo para suprimir destruicao autoimune de celuias beta pancreaticas,formulacao farmaceutica,metodo de profilaxia,metodo para prevenir o surgimento de diabetes tipo 1 e metodo para tratar um mamifero
ES2105926B1 (es) El uso de taxol para la fabricacion de una preparacion de infusion para el tratamiento del cancer.
ES486992A1 (es) Un procedimiento para la preparacion de un derivado de car- boestirilo
IT945980B (it) Superficie e rivestimento compati bili con il sangue o altro tessuto vivo e procedimento epr la loro pre parazione
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
FI51806C (fi) Menetelmä lääkinnässä ja lääkkeiden valmistuksessa käytettävien substi tuoitujen fenyyliasethydroksaamihappojen valmistamiseksi.
HUP0300290A2 (hu) Érkárosító hatású kombinácíós készítmény és terápia
HU9300624D0 (en) Medical preparatives for treating hard tumours containing il-4 as active substance and method for produicng them
DK1167354T3 (da) Racemisk huperzin A
DE69734574D1 (de) Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse
ITMI920710A0 (it) Siringa di sicurezza con ago retrattile dopo l'uso in modo da evitare il riutilizzo della siringa e la diffusione di malattie contagiose per punture accidentali dell'ago.
ES2171459T3 (es) Polvo para administracion nasal de farmaco peptidico o proteinaceo.
IT1032502B (it) Procedimento per la preparazione di liofilizzati o di atomizzati di colaranti e loro impiego per la tintura di figre cheratiniche
ES2036526T3 (es) Composiciones de interferon.
AR019844A1 (es) Polipeptidos composicion farmaceutica, procedimiento para preparar dicha composicion metodo para tratar y prevenir el cancer y metodo para inhibir elcrecimiento de celulas tumorales
ES2086526T3 (es) Aplicacion medicinal de m-csf.
GB1270049A (en) New pharmaceutical product
IT1116880B (it) Composizioni farmaceutiche spray per inalazioni e relativo procedimento di preparazione
Wright et al. In vivo and in vitro effects of chemotherapeutic agents on human neoplastic diseases: a preliminary report on the comparison of the effects of chemotherapeutic agents on human tumors in tissue culture and the effects of each such agent in the patient from whom the tissue for culture was taken
GB1058516A (en) Contrast agent for medical use
ES347271A1 (es) Procedimiento para preparar benzodiazapinas.
USD70500S (en) Design for a dinner wagon

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 649658

Country of ref document: ES